The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract.

The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first material, and a second powder being formed of particles of a second material, wherein the second material is different than the first material. At least some of the particles of the first powder and the second powder are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. In one embodiment, a medical formulation may comprise carbomer present in a range between about 60-80% by weight of the formulation, bentonite present in a range of between about 5-15% by weight of the formulation, and calcium carbonate present in a range of between about 10-30% by weight of the formulation.

The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first material, and a second powder being formed of particles of a second material, wherein the second material is different than the first material. At least some of the particles of the first powder and the second powder are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. In one embodiment, a medical formulation may comprise carbomer present in a range between about 60-80% by weight of the formulation, bentonite present in a range of between about 5-15% by weight of the formulation, and calcium carbonate present in a range of between about 10-30% by weight of the formulation.

The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: —carbomer (poly acrylic acid) in the range from 0.05% to 5%; —sodium hyaluronate in the range from 0.01% to 15%; —poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; —Oryza sativa extract in the range from 0.2% to 20%; and —one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).

The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: —carbomer (poly acrylic acid) in the range from 0.05% to 5%; —sodium hyaluronate in the range from 0.01% to 15%; —poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; —Oryza sativa extract in the range from 0.2% to 20%; and —one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).

The invention concerns removing advanced glycation end products from a bodily fluid by contacting the bodily fluid with a sorbent.

The invention concerns removing advanced glycation end products from a bodily fluid by contacting the bodily fluid with a sorbent.

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

The current disclosure relates to a composition for promoting bone regeneration, preventing or treating bone diseases using a composition containing a hydrogel and a stem cell spheroid and a use thereof, and a method for preparing the same, wherein the composition for bone regeneration has the effect of promoting bone regeneration of injured bone tissue and alleviating pain while promoting the differentiation of the injected mesenchymal stem cells into osteoblasts and osteocytes at the same time, and thus, can be used for the prevention or treatment of bone diseases.

The current disclosure relates to a composition for promoting bone regeneration, preventing or treating bone diseases using a composition containing a hydrogel and a stem cell spheroid and a use thereof, and a method for preparing the same, wherein the composition for bone regeneration has the effect of promoting bone regeneration of injured bone tissue and alleviating pain while promoting the differentiation of the injected mesenchymal stem cells into osteoblasts and osteocytes at the same time, and thus, can be used for the prevention or treatment of bone diseases.